Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05155891 · ClinicalTrials.gov registry record · NA

Investigation of Prostate Artery Embolization Compared to Holmium Laser Enucleation of Prostate

A NA study of Benign Prostatic Hyperplasia, sponsored by University of Miami.

Active
Registry status
NA
Development phase
45
Enrollment target
1
Study location

NCT05155891: Active NA study of Benign Prostatic Hyperplasia, sponsored by University of Miami.

NCT05155891 is a NA study of Benign Prostatic Hyperplasia that is active but no longer recruiting, run by University of Miami. The registered enrollment target is 45 participants, below the 551-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05155891, a NA study of Benign Prostatic Hyperplasia, is active but no longer recruiting, sponsored by University of Miami.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to evaluate prostate artery embolization (PAE) compared to Holmium laser enucleation of prostate (HoLEP) in improving a patient's overall prostate related symptoms.

Primary Outcome

The International Prostate Symptom Score (IPSS) has a total score ranging from 0-35 with the higher score indicating more severe symptoms

Conditions Studied

Benign Prostatic Hyperplasia

Interventions

  • DEVICE Embosphere Microspheres
  • PROCEDURE HoLEP Procedure

Study Locations (1)

Florida

  • University of Miami - Miami

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2022-06-17
Est. Completion 2027-01-01
Phase NA
University of Miami

721 total trials

What the registry record for NCT05155891 still lists

NCT05155891 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 551-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Benign Prostatic Hyperplasia appearing as the primary indexed condition, and to 2 interventions - of which Embosphere Microspheres is the first listed.

NCT05155891 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT05155891 about?

NCT05155891 is a clinical study titled "Investigation of Prostate Artery Embolization Compared to Holmium Laser Enucleation of Prostate". The purpose of this research study is to evaluate prostate artery embolization (PAE) compared to Holmium laser enucleation of prostate (HoLEP) in improving a patient's overall prostate related symptoms.

What is the current status of trial NCT05155891?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2022-06-17. Estimated completion is 2027-01-01.

What conditions does trial NCT05155891 study?

This clinical trial studies the following conditions: Benign Prostatic Hyperplasia.

What interventions are being tested in trial NCT05155891?

The interventions under investigation include: Embosphere Microspheres (DEVICE), HoLEP Procedure (PROCEDURE).

Who is sponsoring clinical trial NCT05155891?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05155891 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Benign Prostatic Hyperplasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05155891's enrollment target sits among peer trials

45 26th of 29 higher than 4 of 29 other Benign Prostatic Hyperplasia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Benign Prostatic Hyperplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05155891, the US trial registry maintained by the National Library of Medicine. NCT05155891 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.